Effect of Adjuvant Trastuzumab for a Duration of 9 Weeks vs 1 Year With Concomitant Chemotherapy for Early Human Epidermal Growth Factor Receptor 2–Positive Breast CancerHeikki Joensuu, Henrik Lindman, Paul Nyandoto et al.|JAMA Oncology|2018Cited by 149
Abstract GS3-04: A randomized phase III study of adjuvant trastuzumab for a duration of 9 weeks versus 1 year, combined with adjuvant taxane-anthracycline chemotherapy, for early HER2-positive breast cancer (the SOLD study)Heikki Joensuu, Henrik Lindman, Jennifer A. Fraser et al.|Cancer Research|2018Cited by 12
Long-Term Outcomes of Adjuvant Trastuzumab for 9 Weeks or 1 Year for <i>ERBB2</i>-Positive Breast CancerHeikki Joensuu, Henrik Lindman, Judith Fraser et al.|JAMA Network Open|2024Cited by 2